z-logo
open-access-imgOpen Access
Is progesterone a worthy candidate as a novel therapy for traumatic brain injury?
Author(s) -
Donald G. Stein
Publication year - 2011
Publication title -
dialogues in clinical neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.11
H-Index - 87
eISSN - 1958-5969
pISSN - 1294-8322
DOI - 10.31887/dcns.2011.13.2/dstein
Subject(s) - neuroactive steroid , traumatic brain injury , medicine , clinical trial , central nervous system , pregnancy , hormone , stroke (engine) , bioinformatics , neuroscience , receptor , psychology , psychiatry , biology , mechanical engineering , gabaa receptor , engineering , genetics
Although progesterone is critical to a healthy pregnancy, it is now known to have other important functions as well. Recent research demonstrates that this hormone is also a potent neurosteroid that can protect damaged cells in the central and peripheral nervous systems and has rapid actions that go well beyond its effects on the classical intranuclear progesterone receptor. Based on years of preclinical research demonstrating its safety and effectiveness in animal models of central nervous system injury the hormone was recently tested in two Phase II clinical trials for traumatic brain injury (TBI). A US National Institutes of Health-sponsored, nationwide Phase III clinical trial is now evaluating progesterone for moderate-to-severe TBI in 1200 patients. An industry-sponsored Phase III international trial is also under way, and planning for a trial using progesterone to treat pediatric brain injury has begun. Preclinical data suggest that progesterone may also be effective in stroke and some neurodegenerative disorders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom